ZVRA NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Zevra Therapeutics Inc. · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 9.53 USD
-25.4% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is -7.4% below the Trend Line and sits at 30.0% of its 52-week range. The latest completed week returned -25.4%, after a -29.5% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 46/100 conviction, while the latest news-sentiment score is 55/100. Near-term considerations: earnings are due in 7d.

Setup score 36 out of 100
Latest Close 9.53 USD 24 Jul 2026
1W Return -25.4% latest completed week
4W Return -29.5% short-term follow-through
12W Return -5.4% quarterly tape
Trend Breadth 46.2% 24 of 52 weeks active
Volume Ratio 1.3x vs 13-week average
What is working
  • The trend backdrop is active with a 13-week active streak.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
  • Activity pressure is constructive, supporting the smart-money activity read.
What could go wrong
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • 3 reversal markers appear in the recent smart-money tape.
  • The share remains more than 20% below its 52-week high.
  • The latest week was a sharp negative move.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -25.4% Latest completed week; four-week move -29.5%. Indicator stack 70/60 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 46/100 conviction; expected move 17.6%. News sentiment 55/100 59 relevant articles in the latest sentiment read. Event risk 7d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is -7.4% below the Trend Line and sits at 30.0% of its 52-week range. The latest completed week returned -25.4%, after a -29.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.3x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.8012-week average 0.66

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership6/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.80Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers33 reversal markers

No recent accumulation markers. 3 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -29.5% over four weeks, -5.4% over 12 weeks, and -15.2% over one year. The current trend has remained active for 13 consecutive weeks.

Performance by holding period

1W-25.4%
4W-29.5%
12W-5.4%
26W6.2%
52W-15.2%
Active trend streak13 weeks
Active weeks in one year24
Trend breadth46.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.72Latest activity-pressure read.
Pressure change-40.9%Four-week change in activity pressure.
Leadership-11.47Latest relative-leadership reading.
RS change-157.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 94% Model confidence 90%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength83/100Blend of value, momentum, and quality. Underlying universe rank 18; rank 1 is best.
Value76/100Relative valuation strength. Underlying universe rank 25; rank 1 is best.
Quality91/100Profitability and accounting quality. Underlying universe rank 10; rank 1 is best.
Momentum25/100Medium-term price momentum. Underlying universe rank 76; rank 1 is best.
Growth90/100Revenue and earnings growth. Underlying universe rank 11; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
4.5x
Price divided by trailing earnings.
Price / sales
4.6x
Market value relative to trailing revenue.
EV / EBITDA
3.3x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
2.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
85.5%
Gross profit retained from each unit of revenue.
Operating margin
112.6%
Operating profit retained from revenue.
Free-cash-flow margin
11.1%
Free cash flow generated from revenue.
Return on invested capital
115.1%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
201.3%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-1.5%
Net share repurchases relative to market value.
Shareholder yield
-1.5%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

ZVRA shows volatility options pressure with a 46/100 conviction score, put-call volume ratio of 0.40, expected move of 17.6%, and Sharemaestro trend signal active.

Conviction46/100
Expected move17.6%
Put/call volume0.40
Pressure37
Speculation42
Volatility91
Trend agreement48
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment55/100

Weighted news tone is neutral across 59 relevant articles.

16 positive · 40 neutral · 3 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings7dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move17.6%Nearest-chain priced movement where available.
52-week drawdown-36.6%Distance below the 52-week high.
13-week volatility11.1%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+19.2%Week of 12 Jun.
Worst week-25.4%Week of 24 Jul.
Latest week-25.4%Week of 24 Jul.

Shape of recent returns

Strong gains6
Modest gains8
Flat weeks0
Modest losses4
Sharp losses8
Recent vol11.1%13-week weekly-return volatility.
Base vol8.8%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew6.5% / -5.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape43/100

Trend, activity pressure, participation, and risk combine to a 43/100 tape read.

 Indicator analysis73/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 6/12.

Activity pressure 0.80; 3 reversal markers Factors70/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 78; Small Cap Core rank 71 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options48/100

ZVRA shows volatility options pressure with a 46/100 conviction score, put-call volume ratio of 0.40, expected move of 17.6%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 17.6% Sentiment55/100

Weighted news tone is neutral across 59 relevant articles.

Zevra Therapeutics (ZVRA) Faces Setback as EMA Panel Rejects Ari Insiders50/100

No recent insider transaction evidence is stored.

 Earnings7d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20269.53 USD-25.4%10.29 USD7.81 USD0.72-11.4710.9MOn
17 Jul 202612.77 USD-4.3%10.27 USD7.78 USD1.1715.944.3MOn
10 Jul 202613.35 USD-4.5%10.12 USD7.73 USD1.2915.729.4MOn
3 Jul 202613.98 USD3.4%9.95 USD7.67 USD1.3322.735.6MOn
26 Jun 202613.52 USD4.8%9.78 USD7.62 USD1.2220.017.6MOn
19 Jun 202612.90 USD2.0%9.61 USD7.56 USD1.249.716.5MOn
12 Jun 202612.65 USD19.2%9.46 USD7.51 USD1.1910.4815.5MOn
5 Jun 202610.61 USD-8.5%9.34 USD7.47 USD1.23-5.188.5MOn
29 May 202611.59 USD15.6%9.28 USD7.44 USD1.42-1.3810.1MOn
22 May 202610.03 USD-8.9%9.23 USD7.40 USD1.31-12.279.6MOn
15 May 202611.01 USD-1.1%9.25 USD7.36 USD1.34-2.899.2MOn
8 May 202611.13 USD10.5%9.24 USD7.33 USD1.25-2.289.7MOn
1 May 202610.07 USD-0.1%9.24 USD7.28 USD1.04-6.794.1MOn
24 Apr 202610.08 USD-5.5%9.23 USD7.25 USD0.91-5.423.5MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.